Barclays analyst Hassan Al-Wakeel lowered the firm’s price target on Fresenius Medical to EUR 38.50 from EUR 39 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care AG Outlines Corporate Objectives
- Fresenius Medical still sees FY24 revenue growth in low- to mid-single digits
- Fresenius Medical reports Q2 EPS EUR0.64 vs. EUR0.48 last year
- Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
- Fresenius Medical Care Sees Strong Q2 Progress